Follow us:
Ypso-Facto invests 1.4M€ in the development of a collaborative software suite for process design and evaluation
The company has received 800k€ from European Regional Development Fund (ERDF) to support the development of Ypso-Proxima®
Nancy, France, January 14th, 2021 - Ypso-Facto, a company specialized in the development and optimization of processes for the Life Sciences Industries invests 1.4M€, including € 800,000 from the European Regional Development Fund (ERDF), to support the development of its software suite Ypso-Proxima®...
NEW ARTICLE - Comparison of mAb single-use DSP processes by Sanofi using Ypso-Proxima
EASY: a disruptive mAb purification process to reduce cost of goods
This article [1] illustrates how Ypso-Proxima allows a rational comparison between two biopharmaceutical DSP processes. The innovative EASY mAb purification process developed by Sanofi is matched against the standard proteinA-based DSP counterpart. Relying on Proxima's process evaluation, the...
NEW ARTICLE – Fareva and Ypso-Facto investigate the purification of an antibiotic by ion-exchange
Using Mechanistic Modeling for Understanding Antibiotics Purification with Ion Exchange Chromatography
This article is based on a real industrial purification process by Fareva and highlights the power of mechanistic modeling for process development: Our client needed to change a raw material to secure his supply chain. From a process point of view, it was supposed to be seamless. However, a...Indépendance sanitaire : La tribune de Roger-Marc Nicoud
“ Retrouver l’indépendance pour la production d’API : une chance pour les CDMO européennes ? "
La crise actuelle rappelle à l’Europe (et sans doute à l’Amérique du Nord) les limites de la délocalisation de la production. C’est le cas pour de nombreux produits, incluant bon nombre d’ingrédients pharmaceutiques actifs (API) et de médicaments en général. Cela ouvre la possibilité...Feature article – Regaining independence in API production: A chance for European CDMOs
Roger-Marc Nicoud, CEO of Ypso-Facto, looks at the challenges and opportunities for CDMOs in the current crisis
The current crisis has highlighted the dependence of European and, indeed, North American countries on delocalised production. This is the case for many goods, including APIs and drugs in general. The opportunity is now there for European CDMOs to win additional business, but effort and adaptation...
COVID-19 STATEMENT
Nancy (France), 25th March 2020
In this unprecedented situation, our number one priority is the safety and well-being of our people and those around us. This is the reason why all our teams are working remotely. Please be assured that, while ensuring everyone’s health and safety, we remain focused on continued service to our...
Ypso-Facto, Your Process Secured and Optimized... it’s a Fact
Product Focus - Chimica Oggi - Chemistry Today customer’s publication
ABOUT YPSO-FACTO Ypso-Facto is a company helping industrial firms to develop, optimize and secure their chemical and bio-processes. We commit to keeping our interests aligned with the ones of our customers. For this reason, we remain deliberately free from industrial property rights, production...
Digitalization for CDMOs: thinking outside the silos!
Panel discussion on custom synthesis and contract manufacturing, Chemistry Today, vol 37(4)
Marc-Olivier Simon and Moïse Bitton discuss the needs of CDMOs in terms of digitalization of their activities and the tools available on the market (ELN, LIMS, LES, SDMS, KM, QMS, MES etc.). While (Big) Pharmas have embraced digitalization, CDMOs seem far behind. The author see this as the result...
Ypso-Facto is a service company helping industrial firms to develop, optimize and secure their chemical processes and bioprocesses.
Download
© Ypso-Facto 2014 - Powered by Ealys | Legal Information